Skip to main content
Lupin Ltd logo

Lupin Ltd — Investor Relations & Filings

Ticker · LUPIN ISIN · INE326A01037 LEI · 335800HHXTESDEE2FC65 BSE.NS Manufacturing
Open in API
Filings indexed 3,180 across all filing types
Latest filing 2022-04-05 Capital/Financing Update
Country IN India
Listing BSE.NS LUPIN

About Lupin Ltd

https://www.lupin.com/

Lupin Ltd is a global pharmaceutical organization specializing in the development, manufacturing, and marketing of a comprehensive range of generic and branded formulations, biotechnology products, and active pharmaceutical ingredients. The company holds a significant market position in therapeutic segments such as cardiovascular, diabetology, asthma, pediatrics, gastrointestinal, anti-infectives, and non-steroidal anti-inflammatory drugs. It is notably recognized for its leadership in the anti-tuberculosis medication sector. With a strong emphasis on research and development, Lupin focuses on complex generics, specialty medicines, and biosimilars. The company operates advanced manufacturing facilities and maintains a substantial commercial presence across major global markets, including North America, Europe, and the Asia-Pacific region, delivering affordable and high-quality healthcare solutions.

Recent filings

Filing Released Lang Actions
Lupin Enters into Licensing Agreement with Alvion to market Cardiometabolic Drugs in the Southeast Asia region.
Capital/Financing Update Classification · 95% confidence The document is a press release announcing that Lupin Limited has entered into a licensing agreement with Alvion Pharmaceuticals to commercialize medicines in Southeast Asia. It is a disclosure pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which relates to material events or information. The content focuses on a business collaboration/licensing agreement, not on financial results, management changes, or regulatory filings. It is not a full financial report, earnings release, or management discussion. The document is a corporate announcement about a licensing agreement, which fits best under Capital/Financing Update (CAP) as it relates to company financing activities and strategic partnerships.
2022-04-05 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release announcing a licensing agreement between Lupin Limited and Alvion Pharmaceuticals to market cardiometabolic drugs in Southeast Asia. It contains no financial statements, no regulatory form references, no voting results, no management changes, no earnings data, and no detailed financial or governance information. The document is relatively short (4219 characters) and serves as a corporate announcement about a business collaboration. This fits best under a general regulatory announcement category rather than a specific financial report or meeting document. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2022-04-05 English
General updates
Capital/Financing Update Classification · 95% confidence The document is a disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, regarding the acquisition of a portfolio of brands from Anglo French Drugs & Industries Limited. It is an announcement of a corporate event related to acquisition activity but does not contain detailed merger or tender offer filings or comprehensive merger documentation. The document is short (1809 characters) and serves as a notification to stock exchanges about a definitive agreement signed for acquisition. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes, including acquisitions that affect company assets and business segments. It is not a full merger filing (MA or TAR), nor a regulatory filing (RNS) since it specifically relates to acquisition disclosure under SEBI regulations. Therefore, the best classification is CAP with high confidence.
2022-04-01 English
Lupin Limited has signed Definitive Agreement with Anglo-French Drugs & Industries Limited for acquiring a portfolio of brands (including all rights and interests associated with such products), ....
Capital/Financing Update Classification · 95% confidence The document is a disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, regarding the acquisition of a portfolio of brands from Anglo French Drugs & Industries Limited. It is an announcement of a transaction related to acquisition activity but does not contain detailed merger or tender offer filings. The document is short (1818 characters) and serves as a notification to stock exchanges about a definitive agreement signed for acquisition. This fits best under Capital/Financing Update (CAP) as it relates to company fundraising or capital structure changes through acquisition announcements, rather than a full merger filing or detailed M&A documentation. Therefore, the classification is CAP with high confidence.
2022-04-01 English
General updates
Regulatory Filings Classification · 100% confidence The document text is extremely short (127 characters) and contains no substantive content, only placeholders for omitted pictures. There is no financial data, no report content, no announcements, or any textual information to classify as a specific report type. Given the lack of content, the document does not fit any specific filing category and defaults to the fallback category for miscellaneous or non-informative filings, which is Regulatory Filings (RNS).
2022-03-31 English
U.S. FDA inspection of the Company''s Somerset, New Jersey (USA) facility. (Revised)
Regulatory Filings Classification · 95% confidence The document is a disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, regarding the U.S. FDA inspection of the company's subsidiary facility. It is an announcement about a regulatory inspection outcome and the company's response, not a full financial report or detailed management discussion. The document length is short (1654 characters) and it serves as a regulatory update rather than a report or presentation. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2022-03-31 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.